Clinical Trial Update: Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 trial of vericiguat in patients with metabolic syndrome and coronary microvascular dysfunction completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Microvascular Dysfunction
• Metabolic Syndrome

Drugs mentioned

• Vericiguat (vericiguat)

Snippet

Sponsor: Johns Hopkins University | Conditions: Metabolic Syndrome, Coronary Microvascular Dysfunction | Phase 2 | Status: COMPLETED | Results posted: 2026-01-27